PROVENGE, an autologous cellular immunotherapy used as a treatment for asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (CRPC). Visit www.provengehcp.com
PROVENGE, an autologous cellular immunotherapy used as a treatment for asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (CRPC). Visit www.provengehcp.com
Sipuleucel-T Impact Trial Video. First in class autologous immunotherapy developed to treat patients with metastatic castrare resistant prostate cancer. Lower Baseline prostate-specific antigen is associated with a greater overall survival benefit from S
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases.
Onyvax is an early-stage biotechnology company focussed on the development of cancer therapies that employ the selectivity and power of the immune system to seek and destroy tumour cells.
Register for the PROVENGE Jumpstart Program. Find information and support in your battle against advanced prostate cancer, visit Provenge.com for more.